Company Overview - Moderna is a commercial-stage biotech founded in 2010, with its IPO in December 2018. The company's mRNA technology gained rapid validation through its COVID-19 vaccine, authorized in the U.S. in December 2020. As of August 2025, Moderna has 35 mRNA development candidates in clinical studies across various therapeutic areas, including infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases [8]. Market Sentiment - Recent options trading indicates a bearish sentiment among deep-pocketed investors towards Moderna, with 55% of notable options leaning bearish and only 33% bullish. This shift in sentiment is significant and suggests that market players should pay attention [1][2]. - The total options activity for Moderna has been extraordinary, with 12 put options totaling $1,840,896 and 6 call options amounting to $311,479 [2]. Price Targets and Trading Activity - Whales have been targeting a price range for Moderna between $30.0 and $50.0 over the last three months, based on the volume and open interest of options contracts [3]. - The average open interest for Moderna options is 531.31, with a total trading volume of 9,720.00. The trading activity has been concentrated within the strike price corridor of $30.0 to $50.0 over the past 30 days [4]. Recent Trading Data - Significant options trades include bearish put options with a total trade value of $1.1 million at a strike price of $42.00, and bullish put options valued at $300,000 with a strike price of $47.00. Additionally, there are neutral and bearish call options with varying trade values and strike prices [7]. Current Market Standing - As of the latest data, Moderna's trading volume is 3,713,575, with the stock price down by 2.71% at $47.39. Analysts have recently adjusted their ratings, with one expert from UBS revising the price target down to $34.0, indicating a neutral stance on the stock [10][11].

CAMBRIDGE, MA / ACCESS Newswire / January 26, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 13, 2026 to report its fourth quarter 2025 financial results, and provide a corporate update. ...

Investment Rating - The report does not explicitly state an investment rating for the industry [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 0.39% from January 19 to January 23, underperforming compared to the Wind All A index, which rose by 1.81% [3][8]. - Key segments such as offline pharmacies (up 9.66%), raw materials (up 2.41%), and pharmaceutical distribution (up 2.28%) showed positive performance, while medical R&D outsourcing (down 3.96%), chemical preparations (down 1.74%), and medical devices (down 0.7%) lagged behind [3][9]. - The personalized tumor vaccine is expected to trigger a significant shift in whole exome sequencing (WES) technology, with Moderna's mRNA personalized tumor vaccine showing a nearly 50% reduction in recurrence or death risk compared to Keytruda alone, based on five-year follow-up data [3][12]. - The report emphasizes the importance of high-quality WES data for the efficacy of mRNA personalized tumor vaccines, suggesting that once validated, WES will transition from an optional to a mandatory diagnostic tool, leading to a value reconstruction in the upstream sequencing industry [3][12]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance from January 19 to January 23 showed a decline of 0.39%, underperforming the Wind All A index, which increased by 1.81% [8]. - Notable gainers included *ST Changyao (up 70.4%), Hualan Biological Engineering (up 32.2%), and Tianzhihang-U (up 27.7%), while major losers were Sunflower (down 37.5%), *ST Changyao (down 33.3%), and Luyuan Pharmaceutical (down 26.6%) [11][12]. Industry News and Key Company Announcements - On January 20, the National Healthcare Security Administration released guidelines for pricing medical services related to surgical and treatment auxiliary operations, which has garnered significant attention in the medical industry [11]. - Moderna and Merck announced that their personalized mRNA vaccine mRNA-4157, in combination with Keytruda, significantly improved recurrence-free survival in high-risk melanoma patients, reducing the risk of recurrence or death by 49% [12][13]. - GSK announced a $2.2 billion acquisition of RAPT Therapeutics, which includes a monoclonal antibody currently in clinical development for food allergies [15]. - The report highlights various companies' performance forecasts, including a projected net profit of -900 million to -995 million for Maiwei Bio, and a significant increase in revenue for JianKai Technology, with expected net profit growth of 101.09% to 121.20% [15][16].

Group 1: Stock Performances - Hecla Mining Company (NYSE:HL) gained 29.31% this week amid rising precious metal stocks due to geopolitical tensions and a weakening US dollar, with expectations of a Fed rate cut [1] - First Majestic Silver Corp. (NYSE:AG) increased by 26.57% this week, following the trend in precious metal stocks [1] - Venture Global, Inc. (NYSE:VG) jumped 21.6% this week after the ICC issued a final arbitration award in favor of the company against Repsol [2] - Moderna, Inc. (NASDAQ:MRNA) rose 17.44% this week due to positive results from a five-year follow-up of a Phase 2b melanoma vaccine trial [2] - New Gold Inc. (AMEX:NGD) gained 24.03% this week, supported by a recommendation from Glass Lewis for shareholders to vote in favor of a merger with Coeur Mining Inc. [3] - Coeur Mining, Inc. increased by 23.13% this week, also benefiting from the merger news with New Gold [3] - United Microelectronics Corporation (NYSE:UMC) jumped 13.82% this week, reflecting positive market sentiment [3] - Micron Technology, Inc. (NASDAQ:MU) rose 13.21% this week after an analyst initiated coverage with an Outperform rating [4] - Korea Electric Power Corporation (NYSE:KEP) gained 15.29% this week, contributing to the overall positive performance in the sector [4] Group 2: Company Guidance and Production - Iamgold Corporation (NYSE:IAG) produced 765,900 ounces of gold in 2025 and provided guidance for 2026, targeting production between 720,000 to 820,000 ounces [4]

格隆汇1月23日｜Moderna跌超3%，该公司不打算投资新的后期疫苗试验。 ...

Group 1 - The core viewpoint of the article is that Moderna's CEO announced the company will not invest in new late-stage vaccine trials due to increasing opposition from U.S. officials regarding vaccine uptake, which significantly reduces the potential market size [1] - The CEO, Stéphane Bancel, stated that without access to the U.S. market, the company cannot achieve a return on investment [1] - Regulatory delays and lack of support from U.S. health officials have been highlighted as key factors contributing to the shrinking market opportunity for Moderna [1] Group 2 - As of January 22, Moderna's stock closed at $51.870, with a pre-market drop of 3.9% to $49.840 on January 23 [2] - The stock's highest price in the last 52 weeks was $55.200, while the lowest was $22.280 [2] - The company's total market capitalization is approximately $20.265 billion, with a trading volume of 34.2435 million shares [2]

Core Insights - The article discusses the author's background as a former investment advisor and business owner, emphasizing a shift to personal investing while continuing to write on financial topics [1]. Group 1 - The author has transitioned from advising clients to investing solely for personal interests [1]. - The author maintains a focus on writing about various financial and economic topics, indicating a commitment to sharing insights and knowledge [1].

Core Viewpoint - The company is experiencing a significant rebound in stock price driven by optimism surrounding upcoming cancer vaccine trial data, despite a history of underperformance and declining vaccine revenue [2][4]. Company Performance - The stock has been a "serial underperformer" with declining top-line revenue from vaccines, but recent optimism is linked to critical data expected from pivotal trials for a cancer vaccine [2]. - The company has made a strategic decision to reduce investment in late-stage vaccine trials in the U.S. due to changing government recommendations, which may impact long-term growth prospects [6][8]. Clinical Data and Trials - Positive data from previous studies has been noted, but concerns exist regarding the baseline characteristics of the current study, which may skew results [3]. - The upcoming pivotal data for melanoma is anticipated to be highly volatile, with management suggesting potential delays into 2027 [5]. Market Sentiment and Stock Valuation - The stock has seen a sharp move upward, influenced by crowded short positions, but the valuation may reflect excessive optimism [4][12]. - The company faces existential risks related to intellectual property disputes, which could impact future margins and balance sheet stability [11]. Future Outlook - The company is navigating a transition from pandemic-driven growth to a focus on its pipeline, with key events expected to influence long-term cash flow generation [10][13]. - The stock is expected to remain extremely volatile as it approaches key cancer conferences later in the year [13].

Moderna is on a roll, with investors hopeful that positive results from a cancer vaccine trial can revive the pharma stock after a stagnant run. ...

Core Insights - Moderna's shares increased by 15.8% following the announcement of positive five-year follow-up data from a phase IIb study on its personalized cancer therapy for high-risk melanoma patients [1][6] Group 1: Study Overview - The KEYNOTE-942/mRNA-4157-P201 study assessed Moderna's mRNA-based individualized neoantigen therapy (intismeran autogene) in combination with Merck's PD-L1 inhibitor, Keytruda, for treating high-risk melanoma patients post-surgery [2][7] - The study showed that the combination therapy significantly improved recurrence-free survival, reducing the risk of recurrence or death by 49% compared to Keytruda alone [3][4] Group 2: Long-term Efficacy and Safety - The follow-up analysis indicated sustained and clinically meaningful improvements in recurrence-free survival, marking a significant milestone for the therapy [3][4] - The safety profile of intismeran autogene combined with Keytruda remained consistent with previous studies [5] Group 3: Future Developments - Moderna and Merck plan to present additional follow-up data at upcoming medical meetings [4][7] - Beyond melanoma, the therapy is being evaluated in pivotal phase III studies for non-small cell lung cancer and other cancer types, with a commercial launch targeted for next year [9] Group 4: Pipeline Expansion - Moderna is focusing on expanding its oncology pipeline, including the development of mRNA-4359, an investigational therapy for melanoma and metastatic non-small cell lung cancer, with data expected in 2026 [10]